Search Results for “Clinical Trial” – Page 109 – media

Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

By Ludwig Burger FRANKFURT (Reuters) – Bayer <BAYGn.DE> agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany’s Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday. The North Carolina-based takeover target, also known as AskBio, is trying to use the harmless adeno-associated virus as a delivery device to bring genetic repair kits against a range of diseases into the body.Drugs and farming pesticides maker Bayer needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer. Among AskBio’s most advanced projects are early tests on volunteers of prospective treatments against Pompe disease – a ...
- Source: drugdu
- 280
- November 2, 2020
Gene therapy
Researchers reveal discovery of new cancer drug fadraciclib

by Institute of Cancer Research Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumors. The drug, called fadraciclib, was jointly discovered by scientists at The Institute of Cancer Research, London, in collaboration with the company Cyclacel. It is already being tested in early clinical trials targeting select hematological malignancies and solid tumors. In a new publication in the journal PLOS One, a team of scientists from Cyclacel and the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR) describe the discovery of fadraciclib, formerly known as CYC065, and describe its mechanism of action and therapeutic properties. Fadraciclib is a leading dual inhibitor of two cancer-driving proteins from the cyclin-dependent kinase (CDK) family, CDK2 and CDK9. CDK2/9 inhibitor It was designed by improving the chemical ...
- Source: drugdu
- 264
- November 1, 2020
fadraciclib
Argentina to co-produce coronavirus vaccine with Mexico

President Alberto Fernández confirms Argentina and Mexico will co-produce millions of doses of a coronavirus vaccine developed by scientists at the University of Oxford and Swedish-British pharma firm AstraZeneca. President Alberto Fernández has announced that Argentina and Mexico will co-produce millions of doses of a coronavirus vaccine developed by the AstraZeneca pharmaceutical firm and scientists at the University of Oxford, with it potentially reaching citizens across Latin America in the first quarter of next year. The Peronist leader, speaking at a press conference at the Olivos presidential residence on Wednesday, said that the two countries would be in charge of the “Latin American production” and distribution of a vaccine created by the prestigious British university and Swedish-British pharmaceutical group. Argentina will be in charge of producing “the active substance,” said Fernández, with Mexico finishing “production and packaging.” He said that the country “could be in a position to vaccinate” by the ...
- Source: drugdu
- 146
- October 31, 2020
FDA Approves First Treatment for COVID-19

For Immediate Release: October 22, 2020 Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. In order to ensure continued access to the pediatric population previously covered under the EUA, the FDA revised the EUA for Veklury to authorize the drug’s use for treatment of suspected or laboratory confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to ...
- Source: drugdu
- 258
- October 26, 2020
Covid-19
Remdesivir becomes first Covid-19 treatment to receive FDA approval

By Maggie Fox, CNN Updated 5:36 PM ET, Thu October 22, 2020 (CNN) The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, said Thursday. It is the first drug to be approved for treating Covid-19. The drug, sold under the brand name Veklury, has been used under emergency use authorization since May. The antiviral has shown, at best, a modest benefit for coronavirus patients. But there is little else available. “In the United States, Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization,” the company said in a statement. “Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.” Earlier this month, a World Health Organization-sponsored global study found remdesivir ...
- Source: drugdu
- 244
- October 23, 2020
Covid-19
UK government signs contract for first coronavirus human challenge studies

By Mick Krever and Phil Black, CNN Updated 4:26 AM ET, Tue October 20, 2020 Why she is volunteering to get infected with Covid-19 03:26 London (CNN) The UK government has signed a contract for the first human challenge studies for the novel coronavirus, in which healthy volunteers are deliberately infected with the virus in a controlled setting, and some receive an experimental vaccine. Up to 19 volunteers at a time will take part in the tests, to be held at the Royal Free Hospital in London, which houses a Biosafety Level 3 ward. They will be run by hVIVO, a medical research company that specializes in running challenge trials, in partnership with Imperial College London. These clinical trials will be a little different from most. For the current Covid-19 vaccine candidates that are in Phase 3 — the final stage of testing — tens of thousands of volunteers are given an experimental ...
- Source: drugdu
- 279
- October 22, 2020
CORONAVIRUS coronavirus vaccine
New Antiviral COVID-19 Treatment to Be Used as Nasal Spray Could Be Made Available Over the Counter

By HospiMedica International staff writers Posted on 08 Sep 2020 An antiviral treatment to be used as a topical nasal spray as prophylaxis against COVID-19 promises to be easy to use, low-cost and quickly made available over-the-counter for consumers. The Nomovid Nasal Spray developed by Parnell Pharmaceuticals (San Rafael, CA, USA) is based upon a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Since it breaks down lipids in the viral envelope, Parnell tested it against the novel coronavirus. “An independent, outside laboratory has confirmed our findings and found it to be greater than 99.9% effective in vitro against the SARS-CoV-2 virus,” said Dr. Francis Parnell, Chairman and CEO of Parnell Pharmaceuticals. “Our product is based upon existing FDA approvals of the active ingredients for use in intravenous and inhalation formulations for other indications. Since the ...
- Source: https://www.hospimedica.com/covid-19/articles/294784405/new-antiviral-covid-19-treatment-to-be-used-as-nasal-spray-could-be-made-available-over-the-counter.html
- 147
- September 9, 2020
Antiviral Used to Treat Coronavirus in Cats Very Likely to Be Effective Drug for COVID-19 Patients

By HospiMedica International staff writers Posted on 31 Aug 2020 A drug used to cure a deadly disease caused by a coronavirus in cats is expected to prove equally effective as a treatment for humans against COVID-19. Researchers at the University of Alberta (Edmonton, Alberta, Canada) are now preparing to launch clinical trials of the drug which is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV. First studied by the University of Alberta researchers following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats. The team synthesized the compounds and tested them against the SARS-CoV-2 virus in test ...
- Source: https://www.hospimedica.com/covid-19/articles/294784252/antiviral-used-to-treat-coronavirus-in-cats-very-likely-to-be-effective-drug-for-covid-19-patients.html
- 182
- September 1, 2020
Moderna coronavirus vaccine shows ‘promising’ safety and immune response results in published Phase 1 study, but more research is needed

(CNN)A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.
- Source: drugdu
- 450
- July 15, 2020
coronavirus vaccine Covid-19 vaccine
DNA Testing of Babies Could Save Lives but Still Raises Questions

A hospital in the US is among the first to offer rapid genome sequencing of critically ill newborns to help identify the cause of their illnesses, which could save their lives. This technology could be used on healthy babies too. But some experts raise concerns about sequencing every baby at birth.
- Source: https://emag.medicalexpo.com/dna-testing-babies-could-save-lives-of-newborns/
- 501
- June 2, 2020
DNA GENETICS genome sequencing NEWBORNS Pediatrics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.